ESMO 2021: Latest in EGFR mutated advanced NSCLC

Bookmark and Share
Published: 11 Oct 2021
Views: 3075
Rating:
Save
Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera

Dr Anna Minchom (The Royal Marsden Hospital, London, UK), Prof Natasha Leighl (Princess Margaret Cancer Centre, Toronto, Canada), Dr Victor Moreno (Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain) and Dr Carlos Cabrera (UOMi Cancer Center, Barcelona, Spain) discuss the updates on EGFR mutated advanced NSCLC from ESMO 2021.

Dr Minchom gives an introduction to EGFR-mutated NSCLC, before Prof Leighl and Dr Cabrera discuss drugs in secondary osimertinib resistance. They mention the analysis from the CHRYSALIS study and the preliminary results from CHRYSALIS-2 study. Dr Minchom then discusses the first-line combo studies with EGFR TKI-angiogenic drugs with Dr Moreno and Prof Leighl. Dr Cabrera also talks about the ORCHARD study and the effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases. They further discuss the Beverly trial and other recent data from ESMO 2021. They conclude by covering some studies regarding the testing for EGFR mutation/ resistance mechanisms.

Analysis from the CHRYSALIS study
PPreliminary results from the CHRYSALIS-2 study
Mechanisms of resistance in EGFR adv NSCLC
Targeted therapies for EGFR adv NSCLC
Toxicity profiles for targeted therapies
ORCHARD study and the effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated NSCLC with brain metastases
Combo studies with EGFR TKI-angiogenic drugs
What to do if a patient progresses?
Discussion on biomarker testing data from ESMO 2021

This programme is supported by an unrestricted educational grant from Janssen.